SecBot SecBot
EFFECT ·Filed Mar 25, 2026

CING

Cingulate Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC9999999995-26-000923
IPO/offering going effective
Actionable Insight • Neutral

Monitor for future prospectus supplements or 8-K filings that may announce actual securities sales under this shelf registration. Traders should be alert to potential near-term dilution if equity is issued.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CING ▼ -21.86% at T+60d
NEUTRAL call -21.86% · α vs SPY -35.31% · entry $6.36 → $4.97
Entry = T+0 close
Mar 25, 2026
via day close
T+1d
-1.26%
call -1.26% · α +0.51%
$6.28
settled 7mo ago
T+5d
-5.50%
call -5.50% · α -5.26%
$6.01
settled 7mo ago
T+20d
-11.64%
call -11.64% · α -19.50%
$5.62
settled 6mo ago
T+60d
-21.86%
call -21.86% · α -35.31%
$4.97
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Cingulate Inc.'s Form S-3 shelf registration has become effective as of March 24, 2026, allowing the company to issue unspecified securities from time to time. This creates a potential for future equity offerings, which may lead to dilution, though no immediate issuance has been announced.

Key Facts

  • Form S-3 shelf registration (File No. 333-292680) became effective on March 24, 2026.
  • The S-3 allows Cingulate Inc. to issue unspecified amounts of securities, including common stock, preferred stock, warrants, or debt, over time and under various conditions.
  • No securities were issued at effectiveness; this is a procedural step enabling future offerings.
  • The company operates in the pharmaceutical preparations sector (SIC 2834) and is incorporated in Delaware.

Financial Impact

Potential future dilution or capital raise of unspecified size; no immediate financial impact.

dilutionequitydebtcash

Risk Factors

  • Future equity issuance could lead to share dilution and downward pressure on stock price.
  • Market perception of a 'dilution overhang' may weigh on sentiment even without immediate offerings.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-000923
Document: 9999999995-26-000923-index.html9999999995-26-000923
Document: 9999999995-26-000923.txt9999999995-26-000923
10 reports for CING
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CING — sortable, filterable
TypeNow
Oct 2, 2026
23d ago
8-K
NEUTRAL ★ 3/10
$4.75awaiting T+60—$4.98 (+4.84%)
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$5.15awaiting T+60—$4.98 (−3.21%)
Aug 13, 2026
10w ago
8-K
NEUTRAL ★ 4/10
$4.99awaiting T+60—$4.98 (−0.20%)
Jul 14, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$4.71 $4.87▲ +3.40%▲ +0.02%$4.98 (+5.73%)
Jun 16, 2026
18w ago
8-K
BULLISH ★ 6/10
$4.74 $5.17▲ +9.07%▲ +8.07%$4.98 (+5.06%)
Jun 8, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$4.65 $5.15▲ +10.75%▲ +6.94%$4.98 (+7.10%)
Mar 25, 2026
30w ago
EFFECT
NEUTRAL ★ 4/10
$6.36 $4.97▼ −21.86%▼ −35.31%$4.98 (−21.70%)
Mar 23, 2026
31w ago
S-3/A
BEARISH ★ 3/10
$6.93 $5.12▲ +26.12%▲ +39.18%$4.98 (+28.14%)
Mar 18, 2026
31w ago
DEFA14A
NEUTRAL ★ 3/10
$7.51 $4.93▼ −34.35%▼ −48.70%$4.98 (−33.69%)
Mar 18, 2026
31w ago
8-K
NEUTRAL ★ 4/10
$8.04 $5.09▼ −36.69%▼ −48.22%$4.98 (−38.06%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 25, 2026